Guardian Pharmacy Services priced an upsized underwritten public offering of 6 million shares of its Class A common stock at $31.00 per share. The offering includes 4,980,000 shares sold by existing stockholders and 1,020,000 shares issued by Guardian as part of a synthetic secondary transaction that allows the company to raise capital while keeping the total number of shares outstanding unchanged. The synthetic secondary structure also enables Guardian to repurchase 1,020,000 shares of Class A common stock from certain stockholders, a transaction that dates back to a corporate reorganization completed in September 2024.
Proceeds from the offering will be used to fund the share repurchase and to support the company’s growth agenda, which includes strategic acquisitions and technology investments that reinforce its lower‑acuity long‑term‑care pharmacy model. Guardian’s business model relies on a technology‑enabled, high‑touch service platform supported by a proprietary data warehouse and a decentralized operational structure, and the capital infusion is intended to accelerate expansion into new markets and to enhance its digital capabilities.
The offering was priced at $31.00 per share, a level that attracted strong investor demand and led to an upsized offering. The transaction was structured to be non‑dilutive, preserving the value of existing shareholders’ holdings while providing fresh equity capital.
Guardian Pharmacy Services operates 61 pharmacies that serve approximately 205,000 residents across 38 states. In FY 2025 the company generated $1.45 billion in revenue, up 18% year‑over‑year, and reported a net income of $49 million, a turnaround from a net loss in 2024. Adjusted EBITDA rose 27% to $115.1 million. The company’s revenue mix is heavily weighted toward Medicare Part D, which accounted for about 71% of FY 2025 revenue, underscoring the importance of payer relationships in its business.
In its Q4 2025 earnings release, Guardian reported an EPS of $0.37 versus the consensus estimate of $0.27, a beat of $0.10, and revenue of $397.6 million versus the consensus estimate of $390.04 million. The company also raised its 2026 Adjusted EBITDA guidance, reflecting confidence in continued execution and disciplined investment. President and CEO Fred Burke highlighted the company’s “broad‑based execution and disciplined investment” during the earnings call, noting that the firm’s operating model remains scalable even amid regulatory changes such as the Inflation Reduction Act.
The non‑dilutive financing structure, combined with the company’s strong financial performance and clear growth strategy, signals robust investor confidence and positions Guardian Pharmacy Services to pursue further expansion while maintaining shareholder value.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.